NeuroNova, Newron deal

Newron said it was unable to get the required two-thirds majority to vote in favor of its proposed acquisition of neurogenesis company NeuroNova. Newron said 66.32% of shares were voted in favor of the deal, below the 66.67% required for approval. Newron said a single shareholder who opposes the deal "significantly increased its stake" before the meeting. Newron said it is considering its options (see BioCentury, June 18). ...